Clinical Trials Logo

Leukemia, Acute Myeloid clinical trials

View clinical trials related to Leukemia, Acute Myeloid.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05362773 Recruiting - Clinical trials for Myelodysplastic Syndromes

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Start date: July 13, 2022
Phase: Phase 1
Study type: Interventional

CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in patients with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic (affect of the drug on the body), immunogenicity (development of antibodies against the drug), and preliminary anti-cancer effect of MGD024. Patients will receive treatment with MGD024 in consecutive 28-day cycles for a study treatment period of up to 12 cycles (approximately 1 year) or until treatment or study discontinuation criteria are met. Response assessments will be performed after Cycle 1 and then after every even numbered cycle starting with Cycle 2 until progression or study treatment discontinuation. Patients will be checked for side effects throughout the study.